Project Grant R01CA266487
Award Date
7/26/22
Completion Date
6/30/27
Dollars Obligated
$732K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $639,742 federal project grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Northwestern University on July 1, 2024. The grant will fund a 3-year research project titled "Harnessing Alternative Splicing to Expand the Tumor Antigen Repertoire and Boost Antitumor Immunity in Glioblastoma." The project aims to investigate innovative approaches to harness alternative splicing mechanisms to expand the repertoire...
This federal Project Grant award of $577,634, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to investigate the role of the SEC61 protein complex in conferring resistance to immunotherapy in glioblastoma (GBM), an aggressive and incurable brain cancer. The research, conducted by Northwestern University, seeks to understand how overexpression of the SEC61G subunit of the SEC61 translocon complex interconnects with the MAPK pathway to...
The federal Project Grant award R35CA283939, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports a research project focused on developing innovative strategies for the treatment of metastatic brain cancer. The $895,779 award to Northwestern University will fund a multi-year effort to: Advance the scientific understanding of how HER2-positive breast cancer metastasizes to the brain by conducting genetic analyses of patient tissue...
The National Cancer Institute (NCI) has awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH). The 5-year grant supports the development of a novel combinatorial therapy to improve treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this grant include: Creating an injectable, biodegradable hydrogel...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,837 to Northwestern University for a 5-year period beginning on August 1, 2024. The grant will support research to develop a new photothermal therapy (PTT) platform using gold nanoparticles and immune stimulants (CPGs) for the treatment of relapsed/refractory B-cell lymphomas. The research aims to characterize the anti-lymphoma immune mechanisms of the PTT/CPG platform,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $661,072 to Northwestern University to develop a first-in-class small molecule inhibitor targeting the USP22 oncogene for the treatment of triple negative breast cancer. The goal is to create a novel therapeutic with both chemo-targeting and immuno-activating properties that can also target cancer stem cells. This work aims to address critical challenges in cancer therapy,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $800,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The research aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant, recurrent brain cancers and plays a key role in tumor growth, immune evasion, and cancer stem cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Northwestern University is focused on advancing the understanding and treatment of cancer by sustaining the metabolic fitness of antitumor CD8+ T cells. The $633,355 award, effective from May 2024 through April 2029, aims to investigate how maintaining the glutathione-glutathione peroxidase 4 (GSH-GPX4) metabolic axis and inhibiting the adenosine A2A receptor can improve the persistence and...
This federal Project Grant award from the National Cancer Institute (93.395 - Cancer Treatment Research) provides funding to Brigham & Women's Hospital Inc. to develop and extensively test a novel cellular therapy platform for treating glioblastoma (GBM), a highly malignant brain tumor. The $417,858 award, effective January 7, 2025 through December 31, 2029, will support the development of engineered mesenchymal stem cells (MSCs) that release bi-specific T-cell engager (BiTE) molecules...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop small molecule inhibitors targeting the interaction between the proteins CHI3L1 and GAL-3 to enhance immunotherapy for glioblastoma (GBM), an aggressive brain cancer. The award, totaling $1,507,764, will fund the optimization of a small molecule inhibitor against...